UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 27, 2005
ZILA, INC.
(Exact Name of Registrant as Specified in its Charter)
| | | | | |
Delaware
(State or Other Jurisdiction of
Incorporation) | | 0-17521
(Commission File Number) | | 86-0619668
(I.R.S. Employer
Identification No.) |
5227 North 7th Street, Phoenix, Arizona 85014-2800
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code(602) 266-6700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form is intended to simultaneously satisfy the filing obligation of the registrant under the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFD 240.14a-12) |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Explanatory Note
This Current Report on Form 8-K/A is filed to amend Item 1.01 in our Current Report on Form 8-K dated June 27, 2005 and filed on June 30, 2005, as set forth below. In line two the word “million” was omitted from the selling price of $11.0 million.
Item 1.01. Entry into a Material Definitive Agreement
On June 27, 2005, Zila Pharmaceuticals, Inc., a subsidiary of Zila, Inc. sold its Zilactin® brand over-the-counter lip and oral care products to Blairex Laboratories, Inc., an Indiana corporation, for approximately $11.0 million in cash. The sale was made pursuant to the Agreement of Purchase and Sale of Assets, dated June 27, 2005 which contained customary representations, warranties and indemnities.
A copy of the press release issued on June 27, 2005 related to the closing of this transaction is filed with this filing as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press release dated June 27, 2005*
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | ZILA, INC.
| |
| Dated: July 6, 2005 | By: | /s/ Andrew A. Stevens | |
| | | Andrew A. Stevens | |
| | | Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | |
| |
EXHIBIT INDEX
| | | |
| EXHIBIT | | |
| NUMBER | | DESCRIPTION |
| *99.1 | | Press release dated as of June 27, 2005 |
| * | | Filed as Exhibit 99.1 to Form 8-K filed June 30, 2005. |
